Unknown

Dataset Information

0

Patented small molecule inhibitors in the ubiquitin proteasome system.


ABSTRACT: Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(R) (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. We review here new patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS components, such as E3 ubiquitin ligases and deubiquitylating enzymes. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

SUBMITTER: Guedat P 

PROVIDER: S-EPMC2106365 | biostudies-literature | 2007 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Patented small molecule inhibitors in the ubiquitin proteasome system.

Guédat Philippe P   Colland Frédéric F  

BMC biochemistry 20071122


Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(R) (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. We review here new patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS components, such  ...[more]

Similar Datasets

| S-EPMC8235664 | biostudies-literature
| S-EPMC4348030 | biostudies-literature
| S-EPMC8226605 | biostudies-literature
| S-EPMC4250122 | biostudies-literature
| S-EPMC6241286 | biostudies-literature
| S-EPMC3185573 | biostudies-literature
2014-10-21 | E-GEOD-59223 | biostudies-arrayexpress
2014-10-22 | E-MTAB-1890 | biostudies-arrayexpress